New eye drop TFC-003 aims to lower glaucoma pressure
Disease control
Recruiting now
This phase 3 trial tests TFC-003, a new eye drop, in 188 adults with primary open-angle glaucoma or ocular hypertension. Participants use the drops twice daily for up to 24 weeks. The main goal is to see if TFC-003 lowers eye pressure better than an active control. The study is c…
Phase: PHASE3 • Sponsor: Kukje Pharma • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC